Document Detail

Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.
MedLine Citation:
PMID:  23151944     Owner:  NLM     Status:  MEDLINE    
Human γδ T cells display potent cytotoxicity against various tumor cells pretreated with zoledronic acid (Zol). Zol has shown benefits when added to adjuvant endocrine therapy for patients with early-stage breast cancer or to standard chemotherapy for patients with multiple myeloma. Although γδ T cells may contribute to this additive effect, the responsiveness of γδ T cells from early-stage breast cancer patients has not been fully investigated. In this study, we determined the number, frequency, and responsiveness of Vγ2Vδ2 T cells from early- and late-stage breast cancer patients and examined the effect of IL-18 on their ex vivo expansion. The responsiveness of Vγ2Vδ2 T cells from patients with low frequencies of Vγ2Vδ2 T cells was significantly diminished. IL-18, however, enhanced ex vivo proliferative responses of Vγ2Vδ2 T cells and helper NK cells from patients with either low or high frequencies of Vγ2Vδ2 T cells. Treatment of breast cancer patients with Zol alone decreased the number of Vγ2Vδ2 T cells and reduced their ex vivo responsiveness. These results demonstrate that Zol can elicit immunological responses by γδ T cells from early-stage breast cancer patients, but that frequent in vivo treatment reduces Vγ2Vδ2 T cell numbers and their responsiveness to stimulation.
Tomoharu Sugie; Kaoru Murata-Hirai; Masashi Iwasaki; Craig T Morita; Wen Li; Haruki Okamura; Nagahiro Minato; Masakazu Toi; Yoshimasa Tanaka
Related Documents :
24676384 - Tryptophan as the fingerprint for distinguishing aggressiveness among breast cancer cel...
23957954 - Combined large cell neuroendocrine carcinoma with giant cell carcinoma of the lungs: a ...
22493624 - Aberrant expression of cancer stem cells marker prominin-1 in low-grade tubulolobular b...
24011664 - C-ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion.
16723304 - Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer.
17047084 - Decreased chicken ovalbumin upstream promoter transcription factor ii expression in tam...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-11-15
Journal Detail:
Title:  Cancer immunology, immunotherapy : CII     Volume:  62     ISSN:  1432-0851     ISO Abbreviation:  Cancer Immunol. Immunother.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-12     Completed Date:  2013-06-07     Revised Date:  2014-04-02    
Medline Journal Info:
Nlm Unique ID:  8605732     Medline TA:  Cancer Immunol Immunother     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  677-87     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / drug therapy,  immunology*,  pathology,  therapy*
Clinical Trials as Topic
Combined Modality Therapy
Diphosphonates / therapeutic use*
Imidazoles / therapeutic use*
Immunotherapy, Adoptive / methods
Interleukin-18 / immunology,  therapeutic use*
Killer Cells, Natural / drug effects,  immunology*
Leukocytes, Mononuclear / immunology
Middle Aged
Neoplasm Staging
Receptors, Antigen, T-Cell, gamma-delta / biosynthesis,  immunology*
T-Lymphocytes, Helper-Inducer / drug effects,  immunology*
Grant Support
Reg. No./Substance:
0/Diphosphonates; 0/Imidazoles; 0/Interleukin-18; 0/Receptors, Antigen, T-Cell, gamma-delta; 118072-93-8/zoledronic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analysis of soluble protein contents from the nematocysts of a model sea anemone sheds light on veno...
Next Document:  Enhancement of the anti-melanoma response of Hu14.18K322A by ?CD40 + CpG.